Alexandria Forbes, MeiraGTx CEO (Hollie Adams/Bloomberg via Getty Images)
December 21, 2023 11:00 AM EST
Deals
Cell/Gene Tx

J&J buys eye dis­ease gene ther­a­py from MeiraGTx, giv­ing the biotech the cash in­fu­sion it was seek­ing

Lei Lei Wu

News Reporter

John­son & John­son pur­chased a gene ther­a­py for X-linked re­tini­tis pig­men­tosa from MeiraGTx for $65 mil­lion up­front, the biotech an­nounced Thurs­day …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Mod­er­na re­ports slow start to RSV sales as Ban­cel steps back from com­mer­cial role

Sarep­ta dis­con­tin­ues work on next-gen ex­on-skip­ping drug for Duchenne

Biotech in­dus­try wor­ries over po­ten­tial for RFK Jr. al­ly as FDA pick

Q&A: Demis Has­s­abis talks win­ning the No­bel Prize, build­ing an AI biotech sans lab, and Trump’s po­ten­tial im­pact

GSK CEO Em­ma Walm­s­ley on the new Trump ad­min­is­tra­tion, trust, AI and Chi­na

sponsored

Gene ther­a­pies don’t have to cost $4 mil­lion: New pro­duc­tion plat­forms re­duce de­vel­op­ment costs and risks

A service from the Financial Times